Mavenclad (cladribine)
- Region
- 🇪🇺 EU
- Active substance
- cladribine
- Company
- Merck Europe B.V.
- Status
- Authorised
- Therapeutic area
- Multiple Sclerosis
- CHMP opinion
- Thu 22 Jun 2017
- EU approval
- Tue 22 Aug 2017
- Application
- EMEA/H/C/004230
- ATC
- L04AA40
- Official record
- www.ema.europa.eu
Indication
Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Litak Authorised · Lipomed GmbH
- 🇪🇺 Movectro Application withdrawn · Merck Serono Europe Limited
Follow Mavenclad
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.